8 in 8 Series: Antithrombotic Medication Use After Bioprosthetic Surgical Aortic Valve Replacement

Although bioprosthetic surgical aortic valve replacement (bio-SAVR) is generally well-tolerated, patients are thought to be at increased risk of thromboembolism for up to 90 days following bio-SAVR, supporting the current guidelines recommending the use of an anticoagulation regimen for at least the first 3 months following bio-SAVR.  This video reviews the current guidelines, literature, and controversy regarding the topic of anticoagulation in bio-SAVR patients. 

Presenters:
Jennifer M. Abelson, MD, MBA, FACC 
Providence St. Peter Hospital

Michael S. Firstenberg, MD, FACC
The Medical Center of Aurora